Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Operating Expenses: 2013-2025

Historic Operating Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to $83.2 million.

  • Ocular Therapeutix's Operating Expenses rose 35.52% to $83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.6 million, marking a year-over-year increase of 51.27%. This contributed to the annual value of $235.5 million for FY2024, which is 67.23% up from last year.
  • As of Q3 2025, Ocular Therapeutix's Operating Expenses stood at $83.2 million, which was up 2.64% from $81.1 million recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Operating Expenses high stood at $83.2 million for Q3 2025, and its period low was $27.6 million during Q1 2021.
  • Its 3-year average for Operating Expenses is $55.9 million, with a median of $60.0 million in 2024.
  • Data for Ocular Therapeutix's Operating Expenses shows a peak YoY spiked of 94.14% (in 2024) over the last 5 years.
  • Ocular Therapeutix's Operating Expenses (Quarterly) stood at $30.4 million in 2021, then increased by 10.14% to $33.4 million in 2022, then rose by 4.23% to $34.9 million in 2023, then spiked by 94.14% to $67.7 million in 2024, then spiked by 35.52% to $83.2 million in 2025.
  • Its Operating Expenses was $83.2 million in Q3 2025, compared to $81.1 million in Q2 2025 and $74.6 million in Q1 2025.